Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) over five years over Washington's request for confidential biological samples.
This move came to light after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesperson later clarified that the US was requesting genetic material for research and profit while was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued dialogue to find a agreement agreeable to all parties so the nation's vital HIV programme can be sustained.
Wider Context
This rejection comes after a comparable situation in Kenya, where a high court blocked a similar deal with the US after legal challenges were raised about the safety of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
According to statements, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"In essence, our country would provide the raw materials for medical research with no assurance that the end products would be available to our citizens if a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending frameworks previously established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," he added.
"We are open to ongoing discussions with our American counterparts on how future collaboration might be designed in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it acknowledged the official position, but urged that talks should continue considering much of the nation's Aids initiatives were funded by external financing.
"In cases where specific concerns exist, including those relating to information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it commented.
The halted deal highlights the ongoing debate between receiving vital foreign assistance and protecting a country's data in an ever more data-driven world.